Myhep All Sofosbuvir 400mg and Velpatasvir 100mg Tablets
- Country of manufactureIndia
- Dosage formPills
MyHepALL is generic of Epclusa.
Contain : Sofosbuvir 400mg And Velpatasvir 100mg
Company : Mylan
MyhepALL Is indicated for the treament fo Hepatitis C.
MyhepAll or Ipclusa should be taken Oncedaily with or without food.
Hepatitis C is a liver disease caused by the hepatitis C virus the virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness.
The hepatitis C virus is a bloodborne virus and the most common modes of infection are through unsafe injection practices, inadequate sterilization of medical equipment, and the transfusion of unscreened blood and blood products.
Globally, between 130–150 million people globally have chronic hepatitis C infection.
A significant number of those who are chronically infected will develop liver cirrhosis or liver cancer.
There is currently no vaccine for hepatitis C; however research in this area is ongoing.
The hepatitis C virus is a bloodborne virus. It is most commonly transmitted through:
- injecting drug use through the sharing of injection equipment;
- the reuse or inadequate sterilization of medical equipment, especially syringes and needles in healthcare settings; and
the transfusion of unscreened blood and blood products.
Sofosbuvir should be used in combination with ribavirin or with pegylated interferon and ribavirin
Sofosbuvir is effective for the treatment of HCV in Genotyp 1 ,Genotype 2 ,Genotype 3 , Genotype 4.
Sofosbuvir and ribavirin therapy for 24 weeks can be considered for patients with genotype 1.
MyhepLvir Sofosbuvir + Ledipasvir show the cure rate of 95 to 97 % In Genotype 1 non Cirrhosis Patient. Myhep Lvir or Harvoni can be used in thr treatment of HIV+HCV Coinfections.
Cure rate means there is no detection of HCV virus in the blood 3 month after treatment is complated.
In Clinical Studies Epclusa Sofosbuvir and Valpatasvir Cure rates are 99 % In genotype 2 and 95% In Genotype 3 Patient.
In Genotype 1 and GT4 and GT5 MyhepAll show the cure rate of 97 to 100%
Side effect with ipclusa or Myhepall in patients with decompensated cirrhosis are fatigue, anemia, nausea, headache, insomnia, and diarrhea.
K M Healthcare is supplier of MYHEPALL, Myhep Lvir, Myhep , Ribavarin, Sofosbuvri Daclastavir Combination or Harvoni Sofosbuvir+ Ledipasvir Combination or Ipclusa Sofosbuvir + Valpatasvir Combnation.
We supply the medicine worldwide . We have client in India, Cambodia, Vietnam , Africa, Russia, China , UK , Europe, Canada , Belarus , Ukraine ,Tazakistan, Iran ,Latin America , Hongkong and many more country .